한글목차

이 보고서는 세계 류마티스 관절염 시장을 조사했으며, 시장 개요, 시판 중인 치료제, 파이프라인 동향, 향후 전망 등의 정보를 제공합니다.

목차

주요 요약

치료 알고리즘

조사 목적

• 시판 치료법
  • Anti-TNFs (Humira, Enbrel, Remicade, Simponi, Cimzia)
  • Interleukin-6 inhibitors (Actemra/RoActemra, Kevzara)
  • Orencia (abatacept; Bristol Myers Squibb)
  • Rituxan/MabThera (rituximab; Biogen/Roche)
  • Xeljanz (tofacitinib; Pfizer)
  • Olumiant (baricitinib; Incyte/Lilly)
  • Rinvoq (upadacitinib; AbbVie)
  • Jyseleca (filgotinib; Galapagos)
• 파이프라인 요법
  • dazodalibep (HZN 4920; Amgen)
• RA 치료에 영향을 미치는 가능성 있는 조기 단계 진행 및 기타 요인
  • 주요 인사이트 요약

부록

영문목차

While use of anti-TNF therapies remains the first line biologic RA treatment choice, prescribing of IL-6 inhibitors has increased. But do KOLs prefer Roche's Actemra/RoActemra or Sanofi's Kevzara? Experts find Amgen's pipeline anti-CD40 ligand-Tn3 fusion protein dazodalibep to be intriguing, but do they see it finding a place in the crowded RA therapy market? KOLs critically assess the prospects of launched and pipeline therapies.

In addition to the full report, licensed users have access to the following KOL Bulletins via the Attachments area.

Companies Listed:

Table of Contents

Executive summary (8)

Treatment algorithm

Research objectives (86)

• Marketed therapies (67)
  • Anti-TNFs (Humira, Enbrel, Remicade, Simponi, Cimzia) (8)
  • Interleukin-6 inhibitors (Actemra/RoActemra, Kevzara) (10)
  • Orencia (abatacept; Bristol Myers Squibb) (10)
  • Rituxan/MabThera (rituximab; Biogen/Roche) (8)
  • Xeljanz (tofacitinib; Pfizer) (10)
  • Olumiant (baricitinib; Incyte/Lilly) (7)
  • Rinvoq (upadacitinib; AbbVie) (8)
  • Jyseleca (filgotinib; Galapagos) (6)
• Pipeline therapies (5)
  • dazodalibep (HZN 4920; Amgen) (5)
• Earlier-stage developments and other factors that may impact RA treatment (12)
  • Key insights summary (12)

Appendix (4)

• KOL details (4)
  • KOLs from the USA (1)
  • KOLs from Europe (2)